Icotyde for Psoriasis: How the First Peptide Pill Compares With Shots and Other Pills

Psoriasis is an immune disease that speeds up the growth of skin cells and leaves thick, scaly patches called plaques, and Johnson & Johnson (J&J) estimates that more than 8 million Americans have it. When creams are not enough, doctors turn to systemic treatments, which work throughout the body. Many of them are biologics, antibody drugs that are made in living cells and given as shots or infusions.

On March 18, 2026, the FDA approved J&J's Icotyde (icotrokinra), a once-daily pill for moderate to severe plaque psoriasis. It is approved for adults and for children 12 and older who weigh at least 40 kg (88 pounds) and are candidates for systemic treatment or phototherapy, a light treatment given in a clinic. The European Commission followed on September 21, 2026. Icotyde blocks the receptor for IL-23, an immune signaling protein that drives psoriasis, while the psoriasis shots Skyrizi and Tremfya block IL-23 itself.

In two trials that tested Icotyde directly against Sotyktu, another psoriasis pill, about 70% of people on Icotyde had clear or almost clear skin after 16 weeks, compared with 50% to 55% on Sotyktu. No finished trial has compared Icotyde with a shot. J&J has not published a list price; analysts estimate it at about $8,285 a month, and our Icotyde pricing guide covers the cost in detail.

A peptide is a short chain of amino acids, the building blocks of proteins. Stomach acid and digestive enzymes break most peptides apart before they can reach the blood, which is why insulin and most GLP-1 weight-loss drugs are injected. Icotrokinra, a 13-amino-acid peptide discovered by J&J and its partner Protagonist Therapeutics, was built to resist that breakdown: in lab tests that J&J scientists published in 2025, it stayed stable in digestive fluids, and it works without an added absorption booster.

Very little of each pill gets into the body. In rats and monkeys, only 0.1% to 0.3% of an oral dose reached the blood, and the FDA label reports that in healthy volunteers, 37% to 81% of a dose came out unchanged in the stool within 24 hours. The drug still works because it binds the IL-23 receptor very tightly, so a small amount in the body can block it. Blood levels peak about 2 hours after a dose and fall by half about every 12 hours, which fits a pill taken every day.

Food matters too. When healthy volunteers took the pill with a high-fat meal, the amount that reached the blood fell by 43%, which explains the label's rule: take it on waking, on an empty stomach, with water, and wait at least 30 minutes before eating.

Psoriasis trials use two standard scores. An IGA score of 0 or 1 means a doctor rated the skin as clear or almost clear, with at least a two-step improvement from the start. PASI 90 means a 90% drop in the Psoriasis Area and Severity Index, a score that combines how much skin is covered with how red, thick, and scaly the plaques are. Both are compared against a placebo, a dummy pill that looks like the drug.

ICONIC-LEAD, published in the New England Journal of Medicine in November 2025, assigned 684 adults and teenagers with moderate to severe psoriasis to Icotyde or placebo, two to one. At week 16, 65% of the Icotyde group had clear or almost clear skin, compared with 8% on placebo; for PASI 90 the figures were 50% and 4%, and 33% versus 1% had completely clear skin. Among the 66 teenagers in the trial, 84% on Icotyde reached clear or almost clear skin, compared with 27% on placebo.

The same trial tested what happens when people stop. Adults who had responded by week 24 were randomly assigned to keep taking Icotyde or to switch to placebo, and among those who had reached PASI 90, 84% who stayed on the drug still had that response at week 52, compared with 21% who switched. For people who stopped, the median time to lose the response was about 10 weeks, so Icotyde controls psoriasis while you take it rather than curing it.

ICONIC-TOTAL, published in NEJM Evidence, enrolled 311 people with psoriasis on the scalp, genitals, hands, or feet, areas that are hard to treat and weigh heavily on daily life. At week 16, 57% on Icotyde had clear or almost clear skin overall, compared with 6% on placebo, and the scalp and genital results also beat placebo, though the hand and foot results did not at that point. J&J reported two-year results on October 2, 2026: 70% of Icotyde-treated patients had clear or almost clear skin at week 112, and complete clearance was 60% on the scalp, 89% in the genital area, and 63% on the hands and feet. Everyone in the trial took the drug after week 16, so those later numbers have no comparison group.

A head-to-head trial assigns similar patients at random to two drugs in the same study and under the same rules, which makes it the fairest way to compare treatments. J&J ran two of these, ICONIC-ADVANCE 1 and 2, against Sotyktu (deucravacitinib), a Bristol Myers Squibb pill that blocks a different immune enzyme called TYK2. The trials enrolled 774 and 731 adults, and the results appeared in The Lancet in September 2025.

Icotyde came out ahead in both trials. In ADVANCE 1, 68% on Icotyde had clear or almost clear skin at week 16, compared with 50% on Sotyktu and 11% on placebo, and in ADVANCE 2 the figures were 71% and 55%. PASI 90 rates were 55% versus 30% in the first trial and 58% versus 34% in the second, and the gap held at week 24, when 66% and 65% on Icotyde reached PASI 90, compared with 41% and 44% on Sotyktu.

The Sotyktu comparisons were secondary goals, but they were set in advance and repeated in two trials, which makes them more convincing than a single result. A J&J-funded follow-up in the British Journal of Dermatology reported that about 70% to 75% of people assigned to Icotyde had clear or almost clear skin from week 24 through week 52, and that side effects were less common on Icotyde than on Sotyktu through week 24. J&J paid for both trials.

No completed trial has tested Icotyde against an injected biologic. J&J's ICONIC-ASCEND trial compares Icotyde with placebo and with Stelara (ustekinumab), an older shot that blocks both IL-12 and IL-23. It enrolled 752 people starting in April 2025, and the registry shows its main data collection ended in November 2025, but J&J had not released results as of early October 2026.

Until then, any comparison with shots is a cross-trial comparison, which lines up results from separate trials as if they came from one. These comparisons mislead because the trials enrolled different people, in different years, with different placebo responses and different rules for counting dropouts. One example is an analysis funded by AbbVie, which sells Skyrizi, that used a statistical method to adjust for some of those differences. It estimated that at week 16, Skyrizi gave a PASI 90 rate 71.4 percentage points above placebo, compared with 49.9 points for Icotyde. A rival drugmaker paid for that analysis, and statistical matching cannot replace randomization, so treat it as a hint rather than proof.

The practical differences are easier to pin down. Icotyde is a pill every morning before food. Skyrizi is a shot at weeks 0 and 4 and then every 12 weeks. Tremfya starts the same way and then comes every 8 weeks, and Stelara follows the Skyrizi schedule with the dose set by body weight. The IL-17 blockers are given more often at first: Cosentyx weekly for five weeks and then every four weeks, Taltz every two weeks until week 12 and then every four weeks, and Bimzelx every four weeks until week 16 and then every 8 weeks. Among the other pills, Sotyktu is taken once a day with or without food, and Otezla, which blocks an enzyme called PDE4, is taken twice a day or as a once-daily extended-release tablet after a starting period.

Icotyde's label has no boxed warning and no list of people who must never take it. Its three warnings cover infections, tuberculosis (TB), and vaccines: doctors should not start it during a significant active infection, should consider a TB test before treatment, and should avoid giving live vaccines while a patient takes it. The label also advises getting all age-appropriate vaccines before starting.

In the four Phase 3 trials, 1,296 people took Icotyde and 568 took placebo for the first 16 weeks. Headache was the most common side effect, at 4.1% versus 3.3% on placebo. Nausea, cough, fungal infections, and tiredness each affected about 1% of people on the drug, and serious infections occurred in 0.2% of Icotyde users and 0.4% of placebo users. The label notes one death from bleeding in the upper digestive tract in a patient who had risk factors, and states that a link to Icotyde has not been established. About 9.6% of people developed antibodies against the drug by week 52, and the label reports no effect of those antibodies on how well it worked.

The routine is strict but simple: swallow the pill whole on waking with water, and wait 30 minutes before eating. People who have trouble swallowing can drop it into at least 4 ounces of water, let it break up, swirl the cup, and drink it within 15 minutes, then add another 4 ounces of water and drink that too. A missed dose can be taken later the same day, with the normal schedule resuming the next morning. In people with moderate or severe kidney disease, blood levels ran about 2.5 to 2.8 times higher, so the label advises watching them for side effects, and there is not enough data on use during pregnancy.

Sotyktu's label differs in two practical ways. It calls for a TB test before treatment rather than leaving it to the doctor's judgment, and it lists rises in triglycerides, a blood fat, and in CPK, a muscle enzyme, which doctors may check with blood tests. The Icotyde label does not list routine blood-test monitoring.

A drug's list price, also called the wholesale acquisition cost (WAC), is what the maker charges wholesalers before discounts and rebates; few patients pay it directly, but it sets the starting point for insurance and cash prices. J&J has not published Icotyde's. In July 2026, analysts at Citizens put it at $8,285 a month, or about $99,400 a year, and on October 5, 2026, GoodRx listed a coupon price of $8,490 for 30 tablets.

That places Icotyde between the older pills and the shots. At list price, Sotyktu costs $7,135.55 a month and Otezla $5,589.89, while Tremfya lists at $14,566.44 a shot and Skyrizi at $23,838.42 a dose, roughly $95,000 and $103,000 a year after the starting doses. Biosimilars, which are close copies of a biologic sold by other companies once the original's patents run out, have cut the price of Stelara: several that launched in 2025 were listed at 80% to 90% below Stelara's $25,497.12 for a 90 mg dose.

With commercial insurance, J&J's savings program can bring the copay to $0, up to a yearly limit. Medicare Part D caps yearly out-of-pocket drug spending at $2,100 in 2026 if a plan covers the drug. Plans may require prior authorization, which means approval before the first fill, and some make patients try a cheaper drug first; the pricing guide lists each program and its limits.

Icotyde is not yet approved for psoriatic arthritis, the joint disease that affects some people with psoriasis, while several shots, including Skyrizi, Tremfya, and Stelara, are. Two Phase 3 trials are under way. ICONIC-PsA 1, in 552 people who had not used biologics, finished collecting its main data in May 2026, according to the registry; its main goal is ACR20, at least a 20% improvement in tender and swollen joints and other standard measures, at week 16. J&J had not reported results as of early October 2026, and ICONIC-PsA 2, with about 750 people, is expected to finish in early 2027.

The drug is also being tested in inflammatory bowel disease. In the Phase 2b ANTHEM-UC trial of 252 adults with ulcerative colitis, J&J reported in October 2025 that 63.5% on the highest dose, 400 mg, had a clinical response at week 12, compared with 27% on placebo. Late-stage trials in ulcerative colitis and Crohn's disease are expected to finish in 2028, and our guide to peptides for ulcerative colitis and Crohn's covers them.

If you are weighing Icotyde, these questions can help your visit:

• Is my psoriasis moderate to severe, and is it on my scalp, genitals, hands, or feet?
• Do I have joint pain that could be psoriatic arthritis? Icotyde is not approved for it.
• Can I take a pill every morning on an empty stomach and wait 30 minutes to eat?
• Do I need a TB test or any vaccines before I start, especially live vaccines?
• Would a shot every 8 or 12 weeks suit me better than a daily pill?
• Does my plan cover Icotyde, and does it require prior authorization or a cheaper drug first?
• Am I pregnant or planning to be, or do I have kidney disease?